Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma

Jemma Dunn, Vasileios Panagiotis Lenis, David A. Hilton, Rolf Warta, Christel Herold-Mende, Clemens Oliver Hanemann, Matthias Futschik

Research output: Contribution to journalArticlepeer-review

34 Downloads (Pure)


Meningioma are the most frequent primary intracranial tumour. Management of aggressive meningioma is complex, and development of effective biomarkers or pharmacological interventions is hampered by an incomplete knowledge of molecular landscape. Here, we present an integrated analysis of two complementary omics studies to investigate alterations in the “transcriptome–proteome” profile of high-grade (III) compared to low-grade (I) meningiomas. We identified 3598 common transcripts/proteins and revealed concordant up- and downregulation in grade III vs. grade I meningiomas. Concordantly upregulated genes included FABP7, a fatty acid binding protein and the monoamine oxidase MAOB, the latter of which we validated at the protein level and established an association with Food and Drug Administration (FDA)-approved drugs. Notably, we derived a plasma signature of 21 discordantly expressed genes showing positive changes in protein but negative in transcript levels of high-grade meningiomas, including the validated genes CST3, LAMP2, PACS1 and HTRA1, suggesting the acquisition of these proteins by tumour from plasma. Aggressive meningiomas were enriched in processes such as oxidative phosphorylation and RNA metabolism, whilst concordantly downregulated genes were related to reduced cellular adhesion. Overall, our study provides the first transcriptome–proteome characterisation of meningioma, identifying several novel and previously described transcripts/proteins with potential grade III biomarker and therapeutic significance
Original languageEnglish
Article number3270
Pages (from-to)1-22
Number of pages22
Issue number11
Publication statusPublished - 5 Nov 2020


Dive into the research topics of 'Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma'. Together they form a unique fingerprint.

Cite this